Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
David Wishart
AddedJun 25, 2026
UpdatedJun 25, 2026
David Wishart

David Wishart

Scientific Advisor, Quinn· 2022 – present · 4 yrs

Wikipedia

David Wishart's Career

Quinn
Quinn

San Francisco, CA, US

Scientific Advisor· Science
2022 – present · 4 yrs

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

David Wishart's Career

Quinn
Quinn
Pre-Seed$1M32022San Francisco, CA, US
Scientific Advisor· Science
2022 – present · 4 yrs

Recent news

‘It’s like Theranos, but it works’: Stanford team plans at-home blood testsSTAT News · 2023
‘Theranos that works’: Stanford researchers say they’ve measured thousands of molecules from a single drop of bloodThe Stanford Daily · 2023
A geneticist studied one drop of his blood – and saw things he couldn't from a vial of bloodUSA TODAY · 2023

Leadership at Quinn

Daniel GomariDaniel GomariFounder and CEO
Brent LaRueBrent LaRueCo-founder
Jan KrumsiekJan KrumsiekCo-founder
Jordan LiptonJordan LiptonMedical Advisory Member
Michael SnyderMichael SnyderScientific Co-founder

Similar to Quinn

ViomeViomeBellevue, WA, USHealth Testing, Supplementsest. 2016ViomeBellevue, WA, US · est. 2016

Bellevue-based Viome offers nutritional genomics testing, gut flora analysis, and personalized dietary advice.

Series C · $276M200
InsideTrackerInsideTrackerCambridge, MA, USHealth Analysisest. 2009InsideTrackerCambridge, MA, US · est. 2009

InsideTracker: Optimizing personal health for longevity and vitality from the inside out.

Series B · $18.2M101
SuperpowerSuperpowerSan Francisco, CA, USBiomarker Testingest. 2023SuperpowerSan Francisco, CA, US · est. 2023

Superpower provides comprehensive biomarker testing and AI-powered longevity protocols for proactive health management.

Series A · $34M166

David Wishart's Similar Executives & Operators

Christopher HenryChristopher HenryScientific Advisor · Gusto GlobalBalfour SartorBalfour SartorScientific Advisor · Gusto GlobalJoshua KorzenikJoshua KorzenikScientific Advisor · Gusto Global

People Similar to David Wishart

David R WilliamsDavid R WilliamsBoard Member · AllDigitalDavid DanielsDavid DanielsCEO · AcadeumDr David R Walt PhDDr David R Walt PhDBoard Member · Arbor BiotechnologiesDr David S WilkesDr David S WilkesBoard Member · Baxter VenturesDavid M WildsDavid M WildsBoard Member · i3 VerticalsDr David LevyDr David LevyBoard Member · Welldoc